Industrial biotechnology for the manufacture of alkaloid pharmaceuticals

用于生产生物碱药物的工业生物技术

• 批准号: LP200301120
• 负责人: Prof Sally Gras
• 金额: $ 37.43万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-12-01 至 2024-11-30
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP200301120
• 关键词: Industrial; biotechnology; manufacture; alkaloid; pharmaceuticals

Drugs that treat opioid dependence and overdose are increasingly needed but their manufacture is difficult, inefficient and expensive. This project aims to develop enzymatic N-demethylation as a simpler and more sustainable approach to the manufacture and modification of opioid antagonists, alkaloids and other drug targets. It will increase our understanding of enzymatic N-demethylation and address engineering and biotechnology challenges to improve yield and product isolation and concentration. Improvements in drug manufacturing processes will assist drug affected communities and industry will benefit from value adding, greater market share and flexibility, increased innovation and de-risked processes and new products.

治疗阿片类药物依赖和过量的药物越来越需要，但它们的制造困难，效率低下且昂贵。该项目旨在开发酶促N-去甲基化作为一种更简单，更可持续的方法来制造和修饰阿片类拮抗剂，生物碱和其他药物靶标。它将增加我们对酶促N-去甲基化的理解，并解决工程和生物技术挑战，以提高产量和产品分离和浓缩。药物制造工艺的改进将有助于受药物影响的社区，药物行业将受益于增值、更大的市场份额和灵活性、更多的创新和降低风险的工艺和新产品。